Black Diamond Therapeutics, Inc. Earnings Per Share Disclosure
| December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Net loss attributable to common stockholders | $ | (69,676) | $ | (82,442) | |||||||
| Weighted average common shares outstanding, basic and diluted | 55,028,371 | 43,954,649 | |||||||||
| Net loss per share, basic and diluted | $ | (1.27) | $ | (1.88) | |||||||
| December 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Options to purchase common stock | 9,434,742 | 8,135,711 | ||||||||||||
| Unvested restricted stock | 540,000 | 20,799 | ||||||||||||
| Shares issuable under employee stock purchase plan | 27,518 | 28,780 | ||||||||||||
Unvested performance restricted stock units | — | 19,000 | ||||||||||||
| Warrants to purchase shares of common stock | 10,757 | 10,757 | ||||||||||||
| 10,013,017 | 8,215,047 | |||||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.